Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EYPT 
Eyepoint Pharmaceuticals Inc (EYPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: EYPT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.69
1 Year Target Price $31.69
| 9 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 300.08% | Avg. Invested days 52 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 647.52M USD | Price to earnings Ratio - | 1Y Target Price 31.69 |
Price to earnings Ratio - | 1Y Target Price 31.69 | ||
Volume (30-day avg) 13 | Beta 1.64 | 52 Weeks Range 3.91 - 13.98 | Updated Date 06/30/2025 |
52 Weeks Range 3.91 - 13.98 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -261.91% | Operating Margin (TTM) -199.72% |
Management Effectiveness
Return on Assets (TTM) -29.16% | Return on Equity (TTM) -53.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 234343167 | Price to Sales(TTM) 11.55 |
Enterprise Value 234343167 | Price to Sales(TTM) 11.55 | ||
Enterprise Value to Revenue 6.6 | Enterprise Value to EBITDA -11.49 | Shares Outstanding 68811696 | Shares Floating 43126379 |
Shares Outstanding 68811696 | Shares Floating 43126379 | ||
Percent Insiders 3.46 | Percent Institutions 109.29 |
Analyst Ratings
Rating 3 | Target Price 31.69 | Buy 4 | Strong Buy 9 |
Buy 4 | Strong Buy 9 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Eyepoint Pharmaceuticals Inc
Company Overview
History and Background
Eyepoint Pharmaceuticals, Inc. (EYPT) was founded in 1987. It is a specialty biopharmaceutical company focused on developing and commercializing innovative ophthalmic products for the treatment of eye diseases. The company's evolution has been marked by a focus on sustained-release drug delivery technologies.
Core Business Areas
- Ophthalmology: Eyepoint focuses on developing and commercializing innovative therapies for eye diseases, utilizing its Durasert sustained-release technology. This includes treatments for chronic conditions such as diabetic retinopathy and uveitis.
Leadership and Structure
The leadership team includes Nancy Lurker (Chief Executive Officer), and other key executives. The organizational structure is typical of a biopharmaceutical company, with departments focused on research and development, clinical trials, manufacturing, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Yutiq: Yutiq is an intravitreal micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Uveitis affects roughly 175,000 people in the USA. Competitors include corticosteroids and other immunosuppressants.
- Lexiscan: Lexiscan (regadenoson) is a pharmacologic stress agent used in myocardial perfusion imaging (MPI). This product was sold in 2022. Market share data is no longer relevant since Eyepoint divested this product.
- Durasert Technology: EyePoint's Durasert technology is a sustained-release drug delivery system used in ophthalmic treatments. It's not a product in itself, but a platform for other drug developments. The market it plays in is the sustained-release drug delivery market within ophthalmology.
Market Dynamics
Industry Overview
The ophthalmology market is experiencing growth driven by an aging population, increased prevalence of eye diseases, and advancements in treatment options. Competition is high among established pharmaceutical companies and emerging biotech firms.
Positioning
Eyepoint is positioning itself as a leader in sustained-release ophthalmic therapies. Its Durasert technology provides a competitive advantage by offering longer-lasting drug delivery, reducing the need for frequent injections. This appeals to physicians and patients.
Total Addressable Market (TAM)
The global ophthalmology market is projected to reach hundreds of billions USD. Eyepoint targets niche segments within this market, such as treatments for specific conditions like uveitis and diabetic retinopathy, allowing it to focus its resources and expertise.
Upturn SWOT Analysis
Strengths
- Proprietary Durasert sustained-release technology
- Approved products like Yutiq
- Experienced leadership team
- Focus on unmet needs in ophthalmology
Weaknesses
- Limited product portfolio
- Reliance on single technology platform
- Small market capitalization
- Dependence on partnerships for development and commercialization
Opportunities
- Expanding indications for existing products
- Developing new products using Durasert technology
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies or products
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles for new products
- Pricing pressures from healthcare payers
- Patent expirations
Competitors and Market Share
Key Competitors
- AGN
- SNY
- VRTX
Competitive Landscape
Eyepoint faces competition from large pharmaceutical companies with established ophthalmology franchises. Its competitive advantage lies in its Durasert technology and focus on niche markets.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product approvals and revenue generation from Yutiq. Collaborative agreements have contributed to non-dilutive funding.
Future Projections: Future growth is projected to come from expansion of existing products, pipeline development, and potential acquisitions. Analyst estimates will vary based on assumptions about product sales and market conditions.
Recent Initiatives: Recent strategic initiatives include expanding the Yutiq label, advancing pipeline programs, and exploring partnerships to broaden its product portfolio.
Summary
EyePoint Pharmaceuticals is a specialty biopharmaceutical company with promising sustained-release technology for ophthalmic diseases. Its product Yutiq, for treating chronic uveitis, drives revenue growth, but the firm faces competition from larger, more established companies. Successful pipeline development and strategic partnerships are crucial for its future growth. While they have proprietary technology, limited funding and competitors pose a threat to growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Investor Relations
- Analyst Reports
- Third-party market research reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share percentages are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eyepoint Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2005-01-27 | President, CEO & Director Dr. Jay S. Duker M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 165 | Website https://eyepointpharma.com |
Full time employees 165 | Website https://eyepointpharma.com | ||
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.